Surface antigen expression and complement susceptibility of differentiated neuroblastoma clones

American Journal of Pathology

Volumn 156, Issue 3, 2000, Pages 1085-1091

  Chen, Shaohua ^a   Caragine, Theresa ^a   Cheung, Nai Kong V ^b   Tomlinson, Stephen ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD59 ANTIGEN; COMPLEMENT; MEMBRANE ANTIGEN; MEMBRANE COFACTOR PROTEIN; MONOCLONAL ANTIBODY;

ANTIGEN EXPRESSION; ARTICLE; CARCINOGENESIS; CELL DIFFERENTIATION; CELL TYPE; HUMAN; HUMAN CELL; MOLECULAR CLONING; NEUROBLASTOMA; PHENOTYPE; PRIORITY JOURNAL;

EID: 0033888697     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)64976-0     Document Type: Article

References (26)

1. Human neuroblastoma cell differentiation
2. Phenotype diversification in human neuroblastoma cells; Expression of distinct neural crest lineages
3. Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells
4. Novel tumor-associated surface antigen: Broad distribution among neurectodermal, mesenchymal and epithelial tumors, with restricted expression among normal tissues
5. CD59, an Ly-6 protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex of homologous cells
6. Distribution of decay-accelerating factor in peripheral blood of normal individuals and patients with paroxysmal nocturnal hemoglobinuria
7. Quantitative analysis of membrane cofactor protein (MCP) of complement
8. Mapping the active site of CD59
9. Complement activation on human neuroblastoma cell lines in vitro: Route of activation and expression of functional complement regulatory proteins
10. Lysis of human tumor cell lines by canine complement plus monoclonal antiganglioside antibodies or natural cannine xenoantibodies
11. Expression of rat CD59: Functional analysis confirms lack of species specificity and reveals that glycosylation is not required for function
12. Expression and function of the complement membrane attack complex inhibitor protectin (CD59) on human breast cancer cells
13. Mapping of epitopes, glycosylation sites, and complement regulatory domains in human decay accelerating factor
14. Complement-mediated tumor cell damage induced by antibodies against membrane cofactor protein
15. Human protectin (CD59), an 18-20 kD complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers
16. Decay-accelerating factor protects human tumor cells from complement mediated cytotoxicity in vitro
17. Monoclonal antibody detection of ganglioside expression in human neuroblastoma
18. Histogenesis and histopathology of neuroblastoma
19. Peripheral tumors of the neurone series
20. Transdifferentiation of neuroblastoma cells
21. Cell lineage and differentiation state are primary determinants of MYCN gene expression and malignant potential in human neuroblastoma cells
22. Transdifferentiation of human neuroblastoma cells results in coordinate loss of neuronal and malignant properties
23. Anti-GD2 antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age
24. 3F8 monoclonal antibody treatment of patients with stage IV neuroblastoma: A phase II study